
SG Bio’s human tissue production facility, 'Novo Factory,' completed a U.S. Food and Drug Administration (FDA) on-site inspection with no findings. Based on international certifications for its existing human tissue processing facilities and experience in exporting to the United States, the company plans to expand its business in the local allograft market.
SG Bio announced on the 17th that Novo Factory, located in Hyangnam, Hwaseong City, Gyeonggi Province, recorded zero findings during the FDA’s on-site inspection of human tissue facilities.
The inspection was conducted from late August to early September. In accordance with regulations regarding Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps), the FDA reviewed key operational procedures and the overall quality management system, covering donor suitability verification for human tissues such as bone and skin, raw material management, processing, storage, distribution, and traceability.
SG Bio received the official inspection report (EIR) from the FDA on the 28th of last month. According to the report, the inspection result was confirmed as 'No Observations' (no findings), and no FDA-483 form, which records findings during inspections, was issued.
Novo Factory is a complex manufacturing facility built by SG Bio for overseas market expansion, receiving completion approval in March of last year. It is capable of producing human tissue processing and medical devices related to bioregenerative medicine, applying the quality management experience accumulated at its existing tissue bank to its production and management systems.
The existing Hyangnam S-Campus, operated separately from Novo Factory, first obtained certification for its human tissue processing quality management system from the American Association of Tissue Banks (AATB) in 2021. It subsequently received recertification in 2024, achieving what the company says is the first consecutive dual certification in South Korea.
SG Bio currently exports allografts to the United States. Based on the results of this FDA inspection, the company plans to expand cooperation with local partners and secure new business opportunities. It also aims to strengthen its supply base in the U.S. market by leveraging Novo Factory’s production and quality management capabilities.
Yoo Hyeon-seung, CEO of SG Bio, stated, "Completing this FDA inspection without any findings is a meaningful achievement that reaffirms the human tissue processing technology and quality management capabilities SG Bio has accumulated over many years." He added, "Going forward, we will continue to enhance our production and quality management systems to meet global regulatory standards, and accelerate business expansion in the U.S. market and strengthening of global partnerships based on stable supply capabilities."